Long-term compliance with antihypertensive therapy: Another facet of chronotherapeutics in hypertension

Blood Pressure Monitoring

Volumn 5, Issue SUPPL. 1, 2000, Pages

  Burnier, Michel ^a,b  

^a Department of Nephrology/Hypertension   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Drug administration schedule; Drug therapy; Hypertension; Patient compliance

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LONG ACTING DRUG;

CHRONOTHERAPY; CLINICAL PRACTICE; DRUG EFFICACY; HUMAN; HYPERTENSION; INTERPERSONAL COMMUNICATION; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033947606     PISSN: 13595237     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126097-200005001-00006     Document Type: Short Survey

References (22)

1. 1 Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys 1960 to 1991. Hypertension 1995; 26:60-69.
2. 2 Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
3. 3 Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens 1999; 21:973-985.
4. 4 Cramer JA. Practical issues in medication compliance. Transplant Proc 1999; 31:7S-9S.
5. 5 The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2466.
6. 6 Vaur L, Vaisse B, Genes N, Elkik F, Legrand C, Poggi L. Use of electronic pill boxes to assess risk of poor treatment compliance. Am J Hypertens 1999; 12:374-380.
7. 7 Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Manag Care 1998; 4:1563-1568.
8. 8 Urquhart J. Patient noncompliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J 1996; 17 (suppl A):8-15.
9. 9 Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. Can Med Assoc J 1999; 160:41-46.
10. 10 Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995; 49:321-327.
11. 11 Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990; 150:1509-1510.
12. 12 Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 1995; 130:572-579.
13. 13 Schneider MP, Fallab Stubi CL, Waeber B, Burnier M. The place of microelectronic systems in measuring compliance. In: J.M. Métry, U.A. Meyer (editors). Drug regimen compliance: issues in clinical trials and patient management. Chichester: John Wiley & Sons Ltd; 1999. pp. 85-96.
14. 14 Waeber B, Vetter W, Dariolp R, Keller U, Brunner HR. Improved blood pressure control by monitoring compliance with antihypertensive therapy. Int J Clin Pract 1999; 53:37-38.
15. 15 Schwed A, Fallab CL, Burnier M, Waeber B, Kappenberger L, Burnand B, et al. Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J Clin Pharmacol 1999; 39:402-409.
16. 16 Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32:345-356.
17. 17 Fallab-Stubi CL, Zellweger JP, Sauty A, Uldry CH, Iorillo D, Burnier M. Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis. Int J Tuberc Lung Dis 1998; 2:525-530.
18. 18 Burnier M, Schneider MP, Chioléro A, Fallab CL, Brunner HR. Objective monitoring of drug compliance: an important step in the management of hypertension resistant to drug therapy [abstract]. Am J Hypertens 1999; 12:29A.
19. 19 Smolensky MH. Knowledge and attitudes of American physicians and public about medical chronobiology and chronotherapeutics. Findings of two 1996 Gallup surveys. Chronobiol Int 1998l; 15:377-394.
20. 20 Buter H, Hemmelder MH, van Paassen P, Navis G, de Zeeuw D, de Jong PE. Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night? Nephrol Dial Transplant 1997; 12 (suppl 2):53-56.
21. 21 Pechère-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann M, Bouroudian HR, et al. Renal response to the AT1 antagonist irbesartan vs enalapril in hypertensive patients. J Hypertens 1998; 16:385-393.
22. 22 Leenen FHH, Fourney A, Notman G, Tanner J. Persistence of antihypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996; 41:83-88.